Trump, tariffs and turmoil: Navigating the regulatory reset

The second Trump administration has ushered in rapid regulatory shifts, with tariffs causing disruption and Robert F. Kennedy Jr. reshaping Food and Drug Administration priorities by slashing staff and reworking agency structure. Key officials at FDA, NIH (National Institutes of Health) and other health bodies have exited, while new federal and congressional priorities are emerging under the administration’s MAHA (Make America Healthy Again) agenda. At the same time, states are stepping in with increasingly aggressive legislation — from restricting minors’ access to supplements to proposing bans on widely used additives. This session will unpack the fast-moving federal and state dynamics, outline key risks and opportunities, and explore how industry can respond strategically to stay ahead and influence what’s next.

Additional fee required.